Skip to main content
Search

# Head and Neck Squamous Cell Carcinoma

2 related articles

Subscribe to updates
  1. bioRxiv

    Head and neck cancer pEMT scores split in two: the malignant arm tracks long progression-free survival on cetuximab, the stromal arm does not

    In head and neck squamous cell carcinoma the partial EMT gene list is expressed by both malignant cells and fibroblasts, yet it has been scored only in bulk tumours. Dividing its 100 genes by the cells that express them shows bulk co-expression is dominated by the stromal arm, so standard pEMT scores mainly measure stroma; a single-cell pseudobulk classifier and a 12-gene malignant core recover the malignant arm in any bulk transcriptome. Among 40 patients given platinum plus cetuximab, both malignant measures were higher in those with long progression-free survival (area under the curve 0.78 and 0.82) and the stromal core was not, but the malignant arm could not be separated from the Basal subtype, which discriminated better (0.93).

  2. GPT-assisted radiomic modeling for predicting pathological complete response to neoadjuvant chemoimmunotherapy in head and neck squamous cell carcinoma

    In a training cohort (n = 186), a validation cohort (n = 116), and a prospective multicenter validation cohort (n = 269), this study extracted radiomic and supervised deep learning features from pretreatment T2-weighted MRI and compared manually developed with GPT-assisted modeling workflows, finding that fused features achieved the highest AUC for both manually developed and GPT-assisted logistic regression models (0.759 versus 0.763 ± 0.003 in the training cohort, 0.714 versus 0.741 ± 0.008 in the validation cohort, and 0.700 versus 0.706 ± 0.

You’re all caught up